CEO: Prabha Fernandes
Ticker: Nasdaq: CEMP
Cempra Pharmaceuticals is developing medicines to meet the increasing need for treating drug-resistant bacterial infections in the community and hospital. The company is using its proprietary chemistry technology to develop macrolides without antibacterial activity for non-antibiotic uses. Cempra held an initial public offering in February 2012.